The short answer
Human evidence on thyroid cancer risk with GLP-1 receptor agonists includes a Scandinavian cohort study in the BMJ, an analysis of 13 obesity-associated cancers in JAMA Network Open, and a 2025 meta-analysis of randomised controlled trials.
Key facts
- Pasternak 2024
- BMJ, Scandinavian cohort (PMID 38683947)
- Wang 2024
- JAMA Netw Open, 13 cancers (PMID 38967919)
- Silverii 2025
- Diabetes Obes Metab, RCT meta-analysis (PMID 40437949)
- Origin of concern
- Rodent toxicology
- Mechanistic context
- Species difference in receptor expression
- Boxed warning
- Remains in place
Why cohort studies suit this question
Thyroid cancer is rare and develops over years. A randomised trial powered to detect a difference in its incidence would need to be impractically large and long. National registry cohorts provide the numbers and the follow-up that trials cannot, which is why the Scandinavian health registries are used for questions of this shape.
What the Scandinavian cohort offers
Pasternak and colleagues published on GLP-1 receptor agonist use and risk of thyroid cancer in the BMJ in April 2024. Scandinavian registries link prescribing, diagnoses and outcomes across whole populations with little loss to follow-up, which removes several biases that weaken cohort studies assembled from other sources.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What a broader cancer analysis adds
Wang and colleagues examined GLP-1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes in JAMA Network Open in July 2024. Looking across many cancer types simultaneously puts any single finding in context. It also requires care, because examining thirteen outcomes raises the chance of one appearing notable by chance alone.
What a meta-analysis of trials contributes
Silverii and colleagues pooled randomised controlled trials in Diabetes, Obesity and Metabolism in 2025. Randomised data avoids confounding by indication, the problem that people prescribed a drug differ from those who are not. Its limitation is duration: pooling trials of a few years cannot address a cancer latency measured in decades.
Why the designs are complementary rather than competing
Trials are randomised but short. Cohorts are long but observational. Neither alone settles a rare, slow-developing outcome, and agreement between designs with different weaknesses is worth more than any single result. That convergence is the strongest form the evidence here can currently take.
How this sits against the warning
The boxed warning derives from rodent toxicology, and Waser and colleagues showed the receptor is not detected in normal human thyroid, a mechanistic reason the rodent finding might not extend. Human studies to date have not produced the signal the rodent data raised. That does not constitute demonstrated absence of risk, and the warning remains on the labels.
What this does not concern
Research material. Every study described here examines licensed medicines prescribed and monitored clinically. Nothing supplied on this site is a GLP-1 receptor agonist or is described by any of this evidence.
Frequently asked questions
Have human studies found increased thyroid cancer?
The cohort and randomised evidence described has not produced the signal the rodent toxicology raised. That is not the same as demonstrated absence of risk.
Why use registry cohorts rather than trials?
Thyroid cancer is rare and slow to develop. A trial powered to detect a difference in its incidence would be impractically large and long.
Has the boxed warning been removed?
No. It remains in place, and removing labelling requires a positive regulatory case rather than accumulating null findings.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedPasternak B et al., Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ 2024 (PMID 38683947)pubmed.ncbi.nlm.nih.gov
- PubMedWang L et al., GLP-1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes. JAMA Netw Open 2024 (PMID 38967919)pubmed.ncbi.nlm.nih.gov
- PubMedSilverii GA et al., GLP-1 receptor agonists and the risk for cancer: a meta-analysis of randomized controlled trials. Diabetes Obes Metab 2025 (PMID 40437949)pubmed.ncbi.nlm.nih.gov
- PubMedWaser B et al. Neuroendocrinology 2011 (PMID 21893952)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- Semaglutide in Obesity-Related Heart FailureKosiborod 2023 in NEJM and a pooled Lancet analysis in 2024. Randomised evidence in HFpEF, which is a stronger design than the observational work.
- STRIDE and the Qualifier That Keeps Getting DroppedA phase 3b randomised trial of semaglutide in symptomatic PAD - and type 2 diabetes. The diabetes criterion is in the title and rarely survives summary.
- A Trial That Had to Move Two Things at Once407 participants, Phase 3, with co-primary endpoints of body weight and WOMAC pain score. Published in NEJM in October 2024.
- A Nationwide Cohort, and a Result That Points Away From the DrugDanish registries, 2009 to 2023. Preterm birth risk was raised in the diabetes indication but not in weight management - which is the finding.
- Canada in January, India in MarchCanada became the first G7 nation where semaglutide patents expired, on 4 January 2026. India followed in March, with generics reported at 70-90% discounts.